 Brian Stauffer
Concepts (466)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelium, Vascular | 38 | 2025 | 901 | 2.890 |
Why?
| | Hypertension | 12 | 2023 | 1242 | 2.510 |
Why?
| | Endothelin-1 | 16 | 2025 | 179 | 2.090 |
Why?
| | Cardiomyopathy, Dilated | 13 | 2025 | 381 | 1.990 |
Why?
| | Vasodilation | 26 | 2025 | 476 | 1.910 |
Why?
| | Heart Ventricles | 11 | 2021 | 781 | 1.410 |
Why?
| | Resistance Training | 2 | 2024 | 151 | 1.410 |
Why?
| | Myocytes, Cardiac | 10 | 2025 | 499 | 1.390 |
Why?
| | Metoprolol | 2 | 2022 | 39 | 1.330 |
Why?
| | Vasoconstriction | 13 | 2025 | 199 | 1.310 |
Why?
| | Fibrinolysis | 10 | 2023 | 137 | 1.270 |
Why?
| | Myocardium | 12 | 2017 | 980 | 1.110 |
Why?
| | Obesity | 20 | 2025 | 2882 | 1.080 |
Why?
| | MicroRNAs | 11 | 2025 | 678 | 1.020 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 127 | 1.010 |
Why?
| | Blood Pressure | 13 | 2022 | 1735 | 1.000 |
Why?
| | Heart Failure | 10 | 2023 | 2149 | 0.910 |
Why?
| | Vasodilator Agents | 21 | 2025 | 326 | 0.900 |
Why?
| | Nebivolol | 3 | 2022 | 9 | 0.900 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 49 | 0.880 |
Why?
| | Cell-Derived Microparticles | 5 | 2025 | 67 | 0.850 |
Why?
| | Postmenopause | 8 | 2023 | 351 | 0.810 |
Why?
| | Exercise | 12 | 2023 | 1924 | 0.800 |
Why?
| | Aging | 14 | 2025 | 1776 | 0.790 |
Why?
| | Overweight | 9 | 2019 | 530 | 0.780 |
Why?
| | Qigong | 1 | 2022 | 1 | 0.780 |
Why?
| | Isoproterenol | 4 | 2018 | 115 | 0.750 |
Why?
| | Forearm | 16 | 2021 | 117 | 0.750 |
Why?
| | C-Reactive Protein | 6 | 2015 | 401 | 0.710 |
Why?
| | Male | 90 | 2025 | 63674 | 0.700 |
Why?
| | Tissue Plasminogen Activator | 11 | 2023 | 222 | 0.680 |
Why?
| | Middle Aged | 71 | 2025 | 31150 | 0.680 |
Why?
| | Nitric Oxide | 8 | 2023 | 902 | 0.660 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1367 | 0.660 |
Why?
| | Cardiolipins | 3 | 2025 | 84 | 0.650 |
Why?
| | Sleep Deprivation | 5 | 2021 | 171 | 0.640 |
Why?
| | Endothelial Cells | 8 | 2025 | 749 | 0.640 |
Why?
| | Mendelian Randomization Analysis | 1 | 2019 | 47 | 0.640 |
Why?
| | Connexin 43 | 3 | 2025 | 29 | 0.630 |
Why?
| | Troponin I | 1 | 2019 | 75 | 0.620 |
Why?
| | Meta-Analysis as Topic | 1 | 2019 | 170 | 0.600 |
Why?
| | Humans | 107 | 2025 | 129622 | 0.600 |
Why?
| | Heart Diseases | 3 | 2013 | 350 | 0.600 |
Why?
| | Regional Blood Flow | 19 | 2025 | 463 | 0.600 |
Why?
| | Mitochondria, Heart | 3 | 2020 | 94 | 0.600 |
Why?
| | Coronary Disease | 2 | 2019 | 385 | 0.590 |
Why?
| | Female | 77 | 2025 | 68770 | 0.590 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 2 | 2017 | 11 | 0.570 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 485 | 0.570 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 527 | 0.560 |
Why?
| | Calcium | 4 | 2021 | 1213 | 0.550 |
Why?
| | Vasoconstrictor Agents | 7 | 2023 | 127 | 0.550 |
Why?
| | Rest | 3 | 2022 | 120 | 0.550 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.540 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 179 | 0.540 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 60 | 0.530 |
Why?
| | Heart Arrest | 1 | 2020 | 321 | 0.520 |
Why?
| | Epoprostenol | 1 | 2017 | 136 | 0.510 |
Why?
| | Sex Characteristics | 6 | 2017 | 737 | 0.500 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 317 | 0.500 |
Why?
| | Testosterone | 3 | 2025 | 372 | 0.490 |
Why?
| | Heart Rate | 2 | 2022 | 801 | 0.480 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 341 | 0.480 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.480 |
Why?
| | YY1 Transcription Factor | 1 | 2015 | 28 | 0.480 |
Why?
| | Acetylcholine | 15 | 2025 | 186 | 0.470 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2017 | 231 | 0.470 |
Why?
| | Muscle Tonus | 3 | 2010 | 21 | 0.470 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1022 | 0.470 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 2004 | 0.460 |
Why?
| | Phosphorylation | 6 | 2021 | 1713 | 0.460 |
Why?
| | Circulating MicroRNA | 3 | 2019 | 25 | 0.440 |
Why?
| | Cardiomegaly | 1 | 2015 | 172 | 0.440 |
Why?
| | Aged | 35 | 2025 | 22099 | 0.420 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 443 | 0.420 |
Why?
| | Adult | 42 | 2025 | 35572 | 0.410 |
Why?
| | Vasomotor System | 2 | 2025 | 44 | 0.410 |
Why?
| | Physical Fitness | 2 | 2024 | 203 | 0.390 |
Why?
| | Transcriptome | 2 | 2021 | 887 | 0.390 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 256 | 0.380 |
Why?
| | Pandemics | 1 | 2020 | 1486 | 0.380 |
Why?
| | Sleep | 5 | 2021 | 685 | 0.380 |
Why?
| | Gene Expression Regulation | 5 | 2016 | 2548 | 0.370 |
Why?
| | Age Factors | 12 | 2025 | 3144 | 0.370 |
Why?
| | Heart | 6 | 2021 | 637 | 0.370 |
Why?
| | Heart-Assist Devices | 2 | 2016 | 539 | 0.360 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 55 | 0.350 |
Why?
| | Stroke | 1 | 2019 | 1071 | 0.350 |
Why?
| | Atherosclerosis | 2 | 2019 | 402 | 0.340 |
Why?
| | Health | 1 | 2010 | 74 | 0.330 |
Why?
| | Body Composition | 7 | 2023 | 649 | 0.330 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 57 | 0.320 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 255 | 0.320 |
Why?
| | Disease | 1 | 2010 | 95 | 0.320 |
Why?
| | Child, Preschool | 14 | 2025 | 10518 | 0.320 |
Why?
| | beta 2-Microglobulin | 1 | 2008 | 49 | 0.310 |
Why?
| | Oligopeptides | 3 | 2025 | 257 | 0.300 |
Why?
| | Physical Endurance | 3 | 2013 | 262 | 0.300 |
Why?
| | Nitroprusside | 13 | 2016 | 67 | 0.300 |
Why?
| | Biomarkers | 12 | 2025 | 3973 | 0.300 |
Why?
| | Prehypertension | 3 | 2014 | 27 | 0.300 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 339 | 0.290 |
Why?
| | Child | 20 | 2025 | 20882 | 0.290 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 758 | 0.290 |
Why?
| | Gender Identity | 2 | 2006 | 122 | 0.290 |
Why?
| | Soybean Proteins | 2 | 2014 | 14 | 0.280 |
Why?
| | Brachial Artery | 3 | 2025 | 192 | 0.280 |
Why?
| | RNA, Messenger | 7 | 2021 | 2708 | 0.270 |
Why?
| | Estrogen Replacement Therapy | 3 | 2013 | 137 | 0.270 |
Why?
| | Reference Values | 4 | 2016 | 793 | 0.250 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 613 | 0.240 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2016 | 46 | 0.240 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2017 | 117 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2440 | 0.240 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 89 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2012 | 0.230 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4063 | 0.220 |
Why?
| | Genomics | 1 | 2008 | 716 | 0.210 |
Why?
| | Cells, Cultured | 5 | 2019 | 4083 | 0.210 |
Why?
| | Analysis of Variance | 6 | 2016 | 1288 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 82 | 0.210 |
Why?
| | Case-Control Studies | 11 | 2025 | 3381 | 0.210 |
Why?
| | Adaptation, Physiological | 3 | 2014 | 513 | 0.210 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 62 | 0.200 |
Why?
| | Animals | 18 | 2025 | 35360 | 0.200 |
Why?
| | Body Weight | 4 | 2023 | 940 | 0.200 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 53 | 0.200 |
Why?
| | Dietary Fats | 2 | 2015 | 301 | 0.200 |
Why?
| | Apoptosis | 6 | 2023 | 2503 | 0.190 |
Why?
| | Baroreflex | 1 | 2022 | 53 | 0.190 |
Why?
| | Proteomics | 1 | 2008 | 1062 | 0.190 |
Why?
| | Systole | 2 | 2021 | 191 | 0.190 |
Why?
| | Cell Movement | 4 | 2014 | 945 | 0.190 |
Why?
| | Down-Regulation | 3 | 2025 | 636 | 0.190 |
Why?
| | Calcium-Binding Proteins | 2 | 2021 | 210 | 0.190 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 388 | 0.190 |
Why?
| | Plethysmography | 6 | 2022 | 107 | 0.190 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2011 | 132 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2021 | 44 | 0.180 |
Why?
| | Myocardial Contraction | 3 | 2019 | 335 | 0.180 |
Why?
| | Hemodynamics | 2 | 2021 | 1089 | 0.180 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2021 | 58 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2011 | 55 | 0.180 |
Why?
| | Vascular Diseases | 1 | 2023 | 241 | 0.180 |
Why?
| | Milrinone | 1 | 2021 | 29 | 0.180 |
Why?
| | Serum | 2 | 2018 | 58 | 0.170 |
Why?
| | Estrogens | 3 | 2012 | 347 | 0.170 |
Why?
| | Spinal Cord Injuries | 1 | 2023 | 194 | 0.170 |
Why?
| | Hyperemia | 1 | 2020 | 48 | 0.170 |
Why?
| | Time Factors | 7 | 2021 | 6556 | 0.170 |
Why?
| | Stem Cells | 3 | 2010 | 577 | 0.170 |
Why?
| | Heart Transplantation | 3 | 2015 | 721 | 0.170 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2022 | 321 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2018 | 505 | 0.160 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 147 | 0.160 |
Why?
| | Cross-Sectional Studies | 12 | 2023 | 5066 | 0.160 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.160 |
Why?
| | Physical Exertion | 2 | 2014 | 205 | 0.160 |
Why?
| | Adolescent | 9 | 2025 | 20391 | 0.160 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 83 | 0.160 |
Why?
| | Telomere | 3 | 2010 | 232 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 877 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.150 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 412 | 0.150 |
Why?
| | Rats | 5 | 2025 | 5499 | 0.150 |
Why?
| | Endothelium | 3 | 2020 | 121 | 0.150 |
Why?
| | Guinea Pigs | 1 | 2018 | 157 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 111 | 0.150 |
Why?
| | Fibrosis | 6 | 2023 | 520 | 0.150 |
Why?
| | Up-Regulation | 3 | 2018 | 840 | 0.150 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 71 | 0.140 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 111 | 0.140 |
Why?
| | Bradykinin | 7 | 2008 | 45 | 0.140 |
Why?
| | HIV | 1 | 2019 | 226 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 249 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 504 | 0.140 |
Why?
| | Walking | 1 | 2022 | 501 | 0.140 |
Why?
| | Blood Flow Velocity | 4 | 2022 | 404 | 0.140 |
Why?
| | Kearns-Sayre Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 30 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2019 | 240 | 0.140 |
Why?
| | Coronary Occlusion | 1 | 2017 | 18 | 0.140 |
Why?
| | Mitochondrial Myopathies | 1 | 2016 | 8 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2017 | 1876 | 0.130 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 56 | 0.130 |
Why?
| | Blotting, Western | 2 | 2016 | 1205 | 0.130 |
Why?
| | Body Mass Index | 7 | 2017 | 2273 | 0.130 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 63 | 0.130 |
Why?
| | Sampling Studies | 1 | 2016 | 96 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 518 | 0.130 |
Why?
| | Caspase 3 | 4 | 2011 | 245 | 0.130 |
Why?
| | Prognosis | 6 | 2018 | 3794 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 164 | 0.130 |
Why?
| | Infant | 6 | 2017 | 9025 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 276 | 0.130 |
Why?
| | Nitric Oxide Synthase Type III | 3 | 2023 | 203 | 0.130 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 1033 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 206 | 0.130 |
Why?
| | Oxidative Stress | 4 | 2022 | 1269 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2020 | 10226 | 0.130 |
Why?
| | Weight Loss | 2 | 2019 | 734 | 0.130 |
Why?
| | Exosomes | 1 | 2017 | 96 | 0.120 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 237 | 0.120 |
Why?
| | Collagen Type III | 1 | 2015 | 14 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2019 | 743 | 0.120 |
Why?
| | Myosin Heavy Chains | 5 | 2014 | 170 | 0.120 |
Why?
| | Mice | 9 | 2015 | 16937 | 0.120 |
Why?
| | Administration, Inhalation | 1 | 2017 | 666 | 0.120 |
Why?
| | Diet | 2 | 2014 | 1213 | 0.120 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 148 | 0.120 |
Why?
| | Action Potentials | 1 | 2018 | 486 | 0.120 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 26 | 0.120 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2014 | 14 | 0.110 |
Why?
| | Ascorbic Acid | 2 | 2021 | 120 | 0.110 |
Why?
| | Cytoskeletal Proteins | 1 | 2015 | 146 | 0.110 |
Why?
| | Lipids | 3 | 2009 | 625 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 129 | 0.110 |
Why?
| | Linear Models | 1 | 2016 | 819 | 0.110 |
Why?
| | Gene Expression | 3 | 2017 | 1472 | 0.110 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 50 | 0.110 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.110 |
Why?
| | Tissue Donors | 1 | 2016 | 391 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1838 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2015 | 239 | 0.110 |
Why?
| | Plasminogen Activator Inhibitor 1 | 4 | 2023 | 84 | 0.110 |
Why?
| | Adiposity | 3 | 2016 | 504 | 0.100 |
Why?
| | Young Adult | 10 | 2023 | 12426 | 0.100 |
Why?
| | Interleukin-6 | 4 | 2022 | 720 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2015 | 2119 | 0.100 |
Why?
| | Phytoestrogens | 1 | 2012 | 17 | 0.100 |
Why?
| | Animals, Newborn | 3 | 2021 | 835 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 187 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 46 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 754 | 0.100 |
Why?
| | Blood Glucose | 4 | 2013 | 2097 | 0.100 |
Why?
| | Piperidines | 2 | 2013 | 198 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 248 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 118 | 0.090 |
Why?
| | Cytokines | 2 | 2010 | 2017 | 0.090 |
Why?
| | Glucose Intolerance | 1 | 2013 | 142 | 0.090 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2017 | 467 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4896 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 331 | 0.090 |
Why?
| | Fatty Acids | 1 | 2014 | 427 | 0.090 |
Why?
| | Abdominal Fat | 1 | 2011 | 40 | 0.090 |
Why?
| | Signal Transduction | 6 | 2016 | 4925 | 0.090 |
Why?
| | Recovery of Function | 1 | 2015 | 642 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 769 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 296 | 0.090 |
Why?
| | Risk Factors | 9 | 2018 | 9763 | 0.090 |
Why?
| | Risk Assessment | 2 | 2016 | 3240 | 0.090 |
Why?
| | Estradiol | 1 | 2013 | 494 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2012 | 177 | 0.080 |
Why?
| | Chemotaxis | 1 | 2010 | 129 | 0.080 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 358 | 0.080 |
Why?
| | RNA | 1 | 2016 | 883 | 0.080 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 252 | 0.080 |
Why?
| | NF-kappa B | 2 | 2023 | 653 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 624 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2406 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 210 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 110 | 0.080 |
Why?
| | Enzyme Inhibitors | 4 | 2017 | 827 | 0.080 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 27 | 0.080 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 59 | 0.070 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 37 | 0.070 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 16 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 381 | 0.070 |
Why?
| | Cell Line | 2 | 2025 | 2781 | 0.070 |
Why?
| | Organ Size | 2 | 2006 | 447 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 161 | 0.070 |
Why?
| | Vascular Stiffness | 1 | 2012 | 467 | 0.070 |
Why?
| | United States | 3 | 2020 | 13900 | 0.070 |
Why?
| | Substance P | 2 | 2008 | 43 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2017 | 5762 | 0.070 |
Why?
| | Adult Stem Cells | 1 | 2006 | 39 | 0.070 |
Why?
| | Protein Isoforms | 2 | 2025 | 391 | 0.060 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 229 | 0.060 |
Why?
| | Hypertrophy | 2 | 2023 | 121 | 0.060 |
Why?
| | Bone Density | 1 | 2010 | 471 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2019 | 1156 | 0.060 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 4 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1706 | 0.060 |
Why?
| | Colony-Forming Units Assay | 3 | 2014 | 90 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2022 | 14519 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 607 | 0.060 |
Why?
| | Mitochondrial Membranes | 1 | 2025 | 39 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 258 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2014 | 530 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2025 | 138 | 0.060 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 133 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2720 | 0.060 |
Why?
| | Triglycerides | 2 | 2005 | 527 | 0.060 |
Why?
| | Diacetyl | 1 | 2003 | 6 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 430 | 0.050 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.050 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.050 |
Why?
| | Quadriplegia | 1 | 2023 | 12 | 0.050 |
Why?
| | von Willebrand Factor | 1 | 2023 | 70 | 0.050 |
Why?
| | Actinin | 1 | 2023 | 13 | 0.050 |
Why?
| | Thrombophilia | 1 | 2023 | 81 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2023 | 101 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 31 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 57 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2017 | 221 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 39 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 1968 | 0.050 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 39 | 0.050 |
Why?
| | Inflammation | 2 | 2019 | 2736 | 0.050 |
Why?
| | Cyclic AMP | 2 | 2014 | 237 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1418 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 250 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1928 | 0.050 |
Why?
| | Premenopause | 1 | 2002 | 121 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 15 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 54 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 132 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 31 | 0.050 |
Why?
| | Vital Capacity | 1 | 2002 | 292 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 118 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 116 | 0.040 |
Why?
| | Oxygen Consumption | 3 | 2012 | 672 | 0.040 |
Why?
| | Lymphocyte Count | 2 | 2011 | 148 | 0.040 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 66 | 0.040 |
Why?
| | Endothelins | 1 | 2021 | 62 | 0.040 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 32 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 241 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 769 | 0.040 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 63 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 457 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 126 | 0.040 |
Why?
| | Cytochromes c | 2 | 2010 | 60 | 0.040 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 79 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2012 | 7084 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 874 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2391 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 209 | 0.040 |
Why?
| | Mice, Inbred C57BL | 4 | 2014 | 5440 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2019 | 57 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 429 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 399 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 559 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 569 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 697 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 191 | 0.040 |
Why?
| | Telomerase | 2 | 2011 | 233 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 442 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 37 | 0.040 |
Why?
| | Electrocardiography | 1 | 2021 | 608 | 0.040 |
Why?
| | Outpatients | 1 | 2021 | 370 | 0.040 |
Why?
| | Disease Progression | 1 | 2006 | 2635 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2019 | 180 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 86 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2025 | 1902 | 0.030 |
Why?
| | Fasting | 2 | 2013 | 267 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 17 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 89 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 55 | 0.030 |
Why?
| | Galectin 3 | 1 | 2016 | 20 | 0.030 |
Why?
| | Electron Transport | 1 | 2016 | 112 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 338 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1206 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 82 | 0.030 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 17 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 174 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 131 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 166 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2470 | 0.030 |
Why?
| | Myogenic Regulatory Factors | 2 | 2006 | 56 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 370 | 0.030 |
Why?
| | MEF2 Transcription Factors | 2 | 2006 | 61 | 0.030 |
Why?
| | Cardiomegaly, Exercise-Induced | 1 | 2014 | 3 | 0.030 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2014 | 33 | 0.030 |
Why?
| | Caseins | 1 | 2014 | 18 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 3717 | 0.030 |
Why?
| | Interleukin-18 | 2 | 2006 | 237 | 0.030 |
Why?
| | Colorado | 2 | 2016 | 4420 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 103 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1622 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 157 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2014 | 95 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 615 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2008 | 521 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 124 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 503 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 191 | 0.030 |
Why?
| | Ventricular Myosins | 2 | 2003 | 36 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2014 | 191 | 0.030 |
Why?
| | Interleukin-1 | 1 | 2016 | 958 | 0.020 |
Why?
| | Genistein | 1 | 2012 | 14 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 496 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 833 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 99 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 137 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 181 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 6 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2012 | 201 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 185 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 390 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 786 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 47 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 122 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 196 | 0.020 |
Why?
| | Waist Circumference | 1 | 2011 | 138 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2006 | 1198 | 0.020 |
Why?
| | Anthropometry | 1 | 2011 | 204 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 182 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2014 | 340 | 0.020 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.020 |
Why?
| | Staurosporine | 1 | 2010 | 20 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 72 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 213 | 0.020 |
Why?
| | Phenotype | 2 | 2011 | 3076 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 316 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 359 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 431 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7131 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 716 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 993 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2008 | 51 | 0.020 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 48 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2564 | 0.020 |
Why?
| | Arm | 1 | 2007 | 107 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2007 | 138 | 0.020 |
Why?
| | Computational Biology | 1 | 2011 | 599 | 0.020 |
Why?
| | Probability | 1 | 2007 | 306 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 127 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2006 | 68 | 0.020 |
Why?
| | Thymidine | 1 | 2005 | 59 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2006 | 79 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2006 | 84 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 141 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.010 |
Why?
| | Glycogen | 1 | 2004 | 55 | 0.010 |
Why?
| | Calmodulin | 1 | 2004 | 76 | 0.010 |
Why?
| | Thrombosis | 1 | 2007 | 343 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 133 | 0.010 |
Why?
| | Sarcomeres | 1 | 2003 | 92 | 0.010 |
Why?
| | Diastole | 1 | 2003 | 148 | 0.010 |
Why?
| | Adenine | 1 | 2005 | 256 | 0.010 |
Why?
| | Cholesterol | 1 | 2005 | 412 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2003 | 426 | 0.010 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 27 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 282 | 0.010 |
Why?
| | Physical Education and Training | 1 | 2003 | 75 | 0.010 |
Why?
| | Vascular Patency | 1 | 2002 | 102 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 92 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 640 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 160 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2002 | 298 | 0.010 |
Why?
| | Potassium | 1 | 2002 | 143 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 171 | 0.010 |
Why?
| | Models, Animal | 1 | 2003 | 376 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2003 | 317 | 0.010 |
Why?
| | Progesterone | 1 | 2003 | 245 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1085 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 384 | 0.010 |
Why?
| | Life Style | 1 | 2003 | 460 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1443 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 5420 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1651 | 0.010 |
Why?
| | Insulin | 1 | 2005 | 2326 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1165 | 0.010 |
Why?
|
|
Stauffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|